K
Kenneth F. Soike
Researcher at Tulane University
Publications - 66
Citations - 2794
Kenneth F. Soike is an academic researcher from Tulane University. The author has contributed to research in topics: Simian varicella virus & Virus. The author has an hindex of 29, co-authored 66 publications receiving 2716 citations. Previous affiliations of Kenneth F. Soike include Anschutz Medical Campus & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Farshad Guirakhoo,Weltzin Richard A,Thomas J. Chambers,Zhenxi Zhang,Kenneth F. Soike,Marion S. Ratterree,Juan Arroyo,K. Georgakopoulos,John Catalan,Thomas P. Monath +9 more
TL;DR: The high replication efficiency, attenuation phenotype in mice and monkeys, immunogenicity and protective efficacy, and genomic stability of ChimeriVax-D2 justify it as a novel vaccine candidate to be evaluated in humans.
Journal ArticleDOI
Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine
Farshad Guirakhoo,Juan Arroyo,Konstantin V. Pugachev,Chuck Miller,Zhenxi Zhang,Weltzin Richard A,K. Georgakopoulos,John Catalan,Simeon W. Ocran,Kenneth F. Soike,Marion S. Ratterree,Thomas P. Monath +11 more
TL;DR: This is the first recombinant tetravalent dengue vaccine successfully evaluated in nonhuman primates and no statistically significant difference in levels of neutralizing antibodies was observed between YF virus-immune and nonimmune monkeys which received the tetraValent YF/DEN1-4 vaccine or between tetraavalent Yf/DEN 1-4- immune and non immune monkeys which receive the YF-VAX.
Journal ArticleDOI
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Thomas P. Monath,Kenneth F. Soike,Inessa S. Levenbook,Zhenxi Zhang,Juan Arroyo,Simon Delagrave,Gwendolyn A. Myers,Alan D.T. Barrett,Robert E. Shope,Marion S. Ratterree,Thomas J. Chambers,Farshad Guirakhoo +11 more
TL;DR: The ability of the ChimeriVax-JE to induce a rapid humoral immune response and to protect against a very severe, direct intracerebral virus challenge is demonstrated and will be applicable to control testing of chimaeric seed viruses and vaccines.
Journal ArticleDOI
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
Thomas P. Monath,Inessa S. Levenbook,Kenneth F. Soike,Zhenxi Zhang,Marion S. Ratterree,Ken Draper,Alan D.T. Barrett,Richard Nichols,Weltzin Richard A,Juan Arroyo,Farshad Guirakhoo +10 more
TL;DR: ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy.
Journal ArticleDOI
Intranasal Monoclonal IgA Antibody to Respiratory Syncytial Virus Protects Rhesus Monkeys against Upper and Lower Respiratory Tract Infection
R. Weltzin,Vicki Traina-Dorge,Kenneth F. Soike,J.-Y. Zhang,P. Mack,G. Soman,G. Drabik,Thomas P. Monath +7 more
TL;DR: It is suggested that nose-drop application of monoclonal antibody could provide convenient and effective protection against RSV infection in human infants at risk of severe lower respiratory tract disease.